Long‐term outcomes after allogeneic versus autologous haematopoietic stem cell transplantation for T‐lymphoblastic lymphoma
British Journal of Haematology · 2026-08 · 209 (2) · 621-631
DOI: 10.1111/bjh.70581 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift British Journal of Haematology, online erschienen am 24.05.2026. Verfasst von Qian Cheng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suz…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Horizontal Research Fundation of Soochow University, Suzhou Science and Technology Development Program - Applied Basic Research (Healthcare) - Science and Technology Innovation Project.
Abstract (Originalsprache)
T‐lymphoblastic lymphoma (T‐LBL) is an aggressive malignancy with a high relapse risk despite intensive therapy. The optimal transplant strategy remains uncertain. We retrospectively analysed 81 patients with T‐LBL undergoing haematopoietic stem cell transplantation (HSCT) (59 allogeneic [allo‐HSCT] and 22 autologous [auto‐HSCT]). Survival outcomes were evaluated using Kaplan–Meier and competing‐risk methods. Multivariable Cox regression, propensity score matching and landmark analyses at 12 months were performed. At 3 years, overall survival (OS) was comparable between allo‐HSCT and auto‐HSCT (76.0% vs. 77.0%; p = 0.890), while progression‐free survival (PFS) was numerically higher following allo‐HSCT (77.0% vs. 58.7%; p = 0.141). The cumulative incidence of relapse tended to be lower after allo‐HSCT (18.6% vs. 30.5%; p = 0.129), with similar non‐relapse mortality. Landmark analyses suggested a time‐dependent pattern, with divergence in PFS beyond 12 months. In multivariable analyses, allo‐HSCT (hazard ratio [HR] 0.34; p = 0.037) and complete remission at transplantation (HR 0.23; p = 0.001) were independently associated with improved PFS, highlighting disease status as a key determinant. Allo‐HSCT showed a trend towards improved disease control without increased non‐relapse mortality. This effect may be influenced by disease status at transplantation. Findings should be interpreted cautiously and require prospective validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, P. R. China.
- Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, P. R. China.
ORCID-Profile: Qian Cheng, Ying Zhu, Qian Wang, Haiwen Huang
Förderung
- Horizontal Research Fundation of Soochow University
- Suzhou Science and Technology Development Program - Applied Basic Research (Healthcare) - Science and Technology Innovation Project
Zitieren
APA
Cheng, Q., Zhu, Y., Sheng, K., Zhou, J., You, T., Wang, Q., Lu, Q., Chen, J., Wu, D., & Huang, H. (2026). Long‐term outcomes after allogeneic versus autologous haematopoietic stem cell transplantation for T‐lymphoblastic lymphoma. British Journal of Haematology, 209(2), 621-631. https://doi.org/10.1111/bjh.70581
Vancouver
Cheng Q, Zhu Y, Sheng K, Zhou J, You T, Wang Q, et al. Long‐term outcomes after allogeneic versus autologous haematopoietic stem cell transplantation for T‐lymphoblastic lymphoma. British Journal of Haematology. 2026;209(2):621-631. doi:10.1111/bjh.70581
BibTeX
@article{Cheng2026,
author = {Cheng, Qian and Zhu, Ying and Sheng, Kaiyu and Zhou, Jin and You, Tao and Wang, Qian and Lu, Qisi and Chen, Jia and Wu, Depei and Huang, Haiwen},
title = {Long‐term outcomes after allogeneic versus autologous haematopoietic stem cell transplantation for T‐lymphoblastic lymphoma},
journal = {British Journal of Haematology},
year = {2026},
volume = {209},
number = {2},
pages = {621--631},
doi = {10.1111/bjh.70581}
}
EUVIMED